Status:
UNKNOWN
Efficacy and Safety of 9MW0813 in Subjects With Diabetic Macular Edema
Lead Sponsor:
Mabwell (Shanghai) Bioscience Co., Ltd.
Conditions:
Diabetic Macular Edema
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Phase III clinical study of the efficacy and safety of 9MW0813 and aflibercept (EYLEA®) in patients with diabetic macular edema (DME) in a multicenter, randomized, double-blind, parallel active-contro...
Detailed Description
This is a multi-center, randomized, double-blind, parallel controlled phase 3 clinical trial. The primary objective is to compare the similarity of clinical efficacy of intravitreal 9MW0813 injection...
Eligibility Criteria
Inclusion
- Main
- Age ≥ 18 years old, gender is not limited;
- Diagnosed with type 1 or type 2 diabetes, and HbA1c≤10.0%;
- The visual impairment of the study eye was mainly caused by diabetic macular edema;
- OCT examination at screening and baseline, diabetic macular edema involving the fovea of the study eye, and central retinal thickness (CRT) ≥ 300 μm (using SD-OCT);
- The best-corrected visual acuity (BCVA) of the study eye at screening and baseline measured using the Early Treatment of Diabetic Retinopathy Study (ETDRS) chart was between 73 and 24 letters (inclusive) (approximately equivalent to Snellen's visual acuity) score 20/40 to 20/320).
- Main
Exclusion
- Active proliferative diabetic retinopathy (PDR) exists in the study eye;
- Structural damage to the fovea in the study eye, which may not improve BCVA after resolution of macular edema (eg, retinal pigment epithelial cell atrophy, subretinal fibrosis or scarring, significant macular ischemia, or organizing hard exudates) );
- The study eye has any ocular disease or past medical history other than diabetic macular edema, and the investigator believes that it may affect the macular assessment or central vision (such as: cataract, retinal vascular occlusion, retinal detachment, macular traction, macular epiretinal membrane , macular hole, macular hemorrhage, preretinal fibrous proliferation involving the macula, various choroidal neovascularization);
- The study eye has erythema of the iris, vitreous hemorrhage or traction retinal detachment;
- The study eye has poorly controlled glaucoma (defined as intraocular pressure ≥25mmHg after anti-glaucoma drug treatment);
- The study eye has received or may have received glaucoma filtration surgery (such as: trabeculectomy, sclerectomy and non-penetrating trabecular surgery) during the study period;
- The study eye has received vitreoretinal surgery in the past;
- Aphakic (except intraocular lens) in the research eye.
Key Trial Info
Start Date :
February 28 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 30 2024
Estimated Enrollment :
346 Patients enrolled
Trial Details
Trial ID
NCT05324774
Start Date
February 28 2022
End Date
July 30 2024
Last Update
April 12 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing tongren hospital affliated to capital medical university
Beijing, Beijing Municipality, China, 100000